# In8bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/in8bio

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.in8bio.com
- Total disclosed funding: $10M
- Latest round: Series A (Jan 3, 2019)
- Investors on record: 1

## About

Based in the US, In8bio, Inc. is a biotechnology company focused on developing gamma-delta T cell therapies for the treatment of cancer, including both solid tumors and hematological malignancies.In8bio, Inc. specializes in innovative immunotherapy solutions, primarily utilizing gamma-delta T cells to target tumors. Founded in 2016, the company's headquarters is located in New York, US. The founders, Lawrence Lamb and William Ho, have extensive experience in the biopharmaceutical sector. The company has raised a total of USD 10.25 mn, with its latest funding round being a Private Placement in August 2022, amounting to USD 10.25 mn. The firm has completed 7 deals to date, with the most recent deal occurring on July 29, 2021.In8bio is dedicated to advancing gamma-delta T cell therapies specifically designed for the treatment of solid tumors and hematological cancers. Its primary investigational products include INB-400, which is in Phase 2 trials for newly diagnosed glioblastoma (GBM), and INB-200, currently undergoing Phase 1 trials targeting GBM. Additionally, INB-100 is in Phase 1 trials for leukemia patients receiving bone marrow transplants. The company employs its proprietary DeltEx™ platform to enhance the efficacy of gamma-delta T cell therapies, distinguishing between healthy and diseased tissues to promote targeted tumor destruction.In8bio's revenue model relies on strategic partnerships with clinical institutions and pharmaceutical companies to fund research and development initiatives. For the most recent year, 2024, the company reported zero revenue with an EBITDA of -USD 27.78 mn. The firm's partnerships typically involve funding for trials, shared development costs, or agreements for the future commercialization of successful therapies, primarily focusing on B2B transactions with healthcare providers in oncology.In8bio aims to utilize its recent funding from the August 2022 Private Placement, amounting to USD 10.25 mn, to advance its immunotherapy technology through both pre-clinical and clinical development programs. The company plans to enhance its product pipeline and expand into European markets alongside its existing North American presence. Upcoming product launches are anticipated to target new cancer therapies that leverage the DeltEx™ platform, further supporting In8bio's mission to provide effective treatment options for patients with cancer.

## Funding rounds

- Series A, Jan 3, 2019, $10M — Bios Partners

## Investors

- Bios Partners (https://capitalatlas.ai/funds/bios-partners) — Series A